Skip to main content
Full access
Letter to the Editor
Published Online: 1 June 1999

Mania Onset While Using Dehydroepiandrosterone

Publication: American Journal of Psychiatry
To the Editor: Steroids are widely recognized as inducing changes in mood, including depression, euphoria, and psychosis with manic symptoms (1). Dehydroepiandrosterone (DHEA) is an adrenal steroid that is transformed into various compounds in many bodily tissues, including skin, muscle, brain, and reproductive organs (2). Adrenal production and serum concentration of DHEA are known to peak between ages 25 and 30 years and thereafter decrease with age. DHEA is widely available over the counter as a dietary supplement and has been widely touted as a fountain of youth and a sexual tonic and promoted for a variety of ills (3). We report a case of severe mania occurring during the use of oral DHEA.
Dr. A, a 51-year-old married man, required involuntary hospitalization because of grandiose delusions, expansive and irritable mood, and extreme psychomotor agitation in May. In January, he had begun taking DHEA, 50 mg daily, to increase his energy level. In retrospect, he denied experiencing depressive symptoms at that time. He was also taking multivitamins and a beef liver extract tablet. Within days of starting to take DHEA, he noted increased energy and a sense of drive. Within 2 weeks, his wife noted gradually worsening psychomotor acceleration, insomnia, irritability, and grandiosity. About a week before hospitalization, he decreased his dose of DHEA to 25 mg/day because of his wife’s concern about his irrational and hyperactive behavior. He had no history of prior mania, depression, or psychiatric treatment. However, his baseline mood status may have been mildly hypomanic, with a high level of energy and drive that had contributed to his professional success. His mother’s half sister had been repeatedly hospitalized for depression, but the family history was otherwise negative for psychiatric disorder, alcoholism, and suicide.
The severity of his psychosis necessitated the appointment of a temporary personal guardian with power of attorney. In the hospital, he responded slowly but well to a combination of haloperidol, 10 mg/day, and divalproex, 1500 mg/day, with serum levels of 81.3 ng/ml. Dr. A’s symptoms disappeared completely over several weeks. As his condition improved, he became increasingly insightful into the extent of his illness and experienced transient mild depressive symptoms in response to feelings of humiliation related to his acute mental illness. Haloperidol treatment was tapered and discontinued without recurrence of psychosis or insomnia, while Dr. A continued receiving divalproex. Four months after his hospitalization, he was symptom free, and he remained well on divalproex monotherapy.
The effect of orally administered DHEA depends on many factors, including serum levels of DHEA and the metabolic status of the body. In most tissues, DHEA is thought to exert antiglucocorticoid effects. DHEA is produced in the central nervous system as well as the human adrenals and is present in the brain, concentrated in limbic regions, in levels much higher than other steroids. DHEA has been postulated to function as an excitatory neuroregulator, antagonizing γ-aminobytyric acid transmission (4). Although it appears possible that Dr. A may have had a bipolar diathesis, oral DHEA may have played a role in the induction of his acute manic episode. Further research is needed to determine the mood effects of DHEA, including its potential risk for patients with bipolar disorder.

References

1.
Peet M, Peter S: Drug-induced mania. Drug Saf 1995; 12:146–153
2.
Crenshaw TL, Goldberg JP: Sexual Pharmacology. New York, WW Norton, 1996
3.
Skolnick AA: Scientific verdict still out on DHEA. JAMA 1996; 276:1365–1367
4.
Robel P, Akwa Y, Compechot C, Hu Z-Y, Jung-Testas I, Kabbadj K, Le Goascogne C, Morfin R, Vourc-h C, Young J, Baulieu E-E: Neurosteroids, in Brain Endocrinology, 2nd ed. Edited by Motta M. New York, Raven Press, 1991, pp 105–132

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 971
PubMed: 10360148

History

Published online: 1 June 1999
Published in print: June 1999

Authors

Affiliations

MARK D. KLINE, M.D.
Laramie, Wy.
ERIC D. JAGGERS, M.D.
Indianapolis, Ind.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share